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Abstract 16 
Purpose: To evaluate the suitability of Galleria mellonella larvae as an in vivo model and drug-17 
screening tool for mycobacteria infections. 18 
Methodology: Larvae were infected using a range of inoculum sizes from a variety of rapid-growing 19 
mycobacteria, including strains of M. fortuitum, M. marinum and M. aurum. Larval survival, internal 20 
bacterial burden, and the effects of amikacin, ciprofloxacin, ethambutol, isoniazid and rifampicin 21 
treatment on larval survival were measured over 144h. The effects of these anti-mycobacterial drugs 22 
on phagocytosis and circulating hemocyte numbers were also examined using microscopy.  23 
Results: Larval survival decreased after infection with M. fortuitum and M. marinum in a dose-24 
dependent manner, but remained unaffected by M. aurum. Heat-killed bacteria did not cause larval 25 
death. Where antibiotic monotherapy was efficacious, larval survival post-infection increased in a 26 
dose-dependent fashion. However, efficacy varied between different antibiotics and species of 27 
infecting mycobacteria and, apart from rifampicin, efficacy in vivo correlated poorly with the in vitro 28 
MICs. Combinations of antibiotics led to higher survival of infected larvae than antibiotic 29 
monotherapy. Selected antibiotic treatments that enhanced larval survival reduced the overall 30 
internal burden of infecting mycobacteria but did not eradicate the pathogens. Administration of 31 
amikacin or ethambutol to uninfected larvae induced an initial transient increase in the numbers of 32 
circulating hemocytes and reduced the phagocytic rate of hemocytes in larvae infected with M. 33 
marinum.  34 
Conclusions: This report demonstrates the potential of employing a wax moth larvae model for 35 
studying fast-growing mycobacteria infections, and as a cheap, effective system for initial screening 36 
of novel treatments.   37 
Introduction 38 
Mycobacteria species, primarily Mycobacterium tuberculosis, are major human pathogens 39 
and a significant cause of morbidity and mortality. Multidrug resistant tuberculosis (TB) is now a global 40 
challenge with around 480,000 new MDR-TB cases in 2015 [1]. Extensively drug resistant cases were 41 
reported in 96 countries in 2012 [2] and “totally drug resistant” cases have been described in several 42 
countries [3–6].  Using M. fortuitum [12, 13], M. marinum [14, 15] and M. aurum [8, 11] as surrogates 43 
for M. tuberculosis is well established, both in vitro and in vivo, but M. fortuitum and M. marinum are 44 
important infectious bacteria in their own right. Infections with either bacteria have no reporting 45 
requirements, but estimates of incidence are 4.65-5.99 cases per million persons for M. fortuitum [16] 46 
and 0.05-0.27 case per 100,000 adult patients for M. marinum [17]. These mycobacteria have similar 47 
host-pathogen interactions [7], cell wall profiles [8], membrane and efflux pump proteins [9], virulence 48 
genes [10] and drug resistance profiles [11] compared with M. tuberculosis, but are much less capable 49 
of infecting an immunocompetent human and generally have a much faster growth rate.  50 
A rapid screening model is needed to assess effective treatment combinations and expedite 51 
discovery of novel therapies for mycobacteria. Using wax moth larvae, Galleria mellonella, as an in 52 
vivo model to assess the virulence of pathogens and the efficacy of antimicrobials is well established 53 
(reviewed in [18, 19]). Their small size, low purchase and maintenance costs, and reduced ethical 54 
controls means they are accessible to most laboratories. Many experiments require minimal 55 
“specialised” equipment, and larvae can be incubated at 37°C and easily inoculated with precise 56 
volumes – a significant advantage over other invertebrate models such as fruit flies and nematodes 57 
that are not viable at 37°C for extended incubations and are awkward to inoculate. The wax moth 58 
larvae model can be a valuable screening tool to highlight treatment combinations, novel compounds 59 
and alternative therapies that can then be assessed in mammalian trials. 60 
Compared to mammals,  G. mellonella lacks an adaptive immune system, yet the invertebrate 61 
innate immune system is very robust, with complex cellular defences and production of at least 18 62 
antimicrobial peptides [20]. Vertebrate white blood cells and invertebrate hemocytes are not 63 
homologous, however they do have analogous roles including wound repair [21], cell clustering 64 
around foreign bodies [22], innate immunity [23], phagocytosis [24], and production of reactive 65 
oxygen species as a defence mechanism [23]. 66 
Using a cheap and rapid in vivo model to reliably model mycobacterial treatments is clearly 67 
attractive. Considering the advantage of using a model organism which negates the requirement of 68 
specialised laboratories and ethical approval, it is equally advantageous (for the reasons stated above) 69 
to use non-tuberculosis mycobacteria species such as M. fortuitum, M. marinum and M. aurum , since 70 
M. tuberculosis  is a highly pathogenic bacterium capable of infecting immunocompetent individuals 71 
[25] and requires weeks of incubation before cultures are ready to use. This report aims to 72 
demonstrate the suitability of G. mellonella as a model for mycobacteria infections, allowing 73 
application of the model as a cheap, efficient and rapid in vivo screen for antibiotic combinations and 74 
novel treatments that may be effective against M. tuberculosis infections.  75 
Materials and Methods 76 
Reagents and larvae 77 
Reagents were purchased from Sigma-Aldrich Ltd (Dorset, UK) unless stated otherwise. 78 
Antibiotics were dissolved in sterile deionised water. Larvae were purchased from UK Waxworms Ltd 79 
(Sheffield, UK), stored in the dark at 20°C and used within 7 days of receipt. Injections were performed 80 
with a 25 µL Hamilton syringe. Larvae were incubated at 37°C in petri dishes in all experiments. 81 
Bacteria and growth media 82 
M. fortuitum NCTC 10394 and NCTC 8573, M. marinum Strain M and R356933F, and M. aurum 83 
NCTC 10437 were purchased from the National Collection of Type Cultures (Porton Down, Salisbury). 84 
M. marinum R356933F was kindly provided by Michael Smith (Scottish Mycobacteria Reference 85 
Laboratory, Royal Infirmary of Edinburgh). Bacteria were cultured in a shaking incubator using 86 
Mueller-Hinton M7H9 broth enriched with albumin dextrose catalase (ADC) overnight at 37°C for M. 87 
aurum and M. fortuitum strains, and at 27°C for approximately 36h for M. marinum strains. Any agar 88 
plates used were Mueller-Hinton M7H9 broth enriched with ADC supplement and 10% agar, except 89 
for the selective plates used in the burden experiment, which included piperacillin (PIP) at 256 mg/L.  90 
Prior to all inoculations, all bacteria were washed twice and diluted to the required 91 
concentration using PBS. Heat-killing was performed in a 100°C water bath for 10 minutes and loss of 92 
viability confirmed by plating out as above. 93 
Antibiotic susceptibility testing 94 
The minimum inhibitory concentration (MIC) of each antibiotic against M. fortuitum NCTC 95 
10394 and NCTC 8573, and M. marinum Strain M and R356933F was determined using MIC strips 96 
(AMK and CIP, Oxoid, UK. EMB, INH and RIF, Liofilchem, Italy) according to manufacturer instructions. 97 
Cells were plated at 2.5 x 106 c.f.u per 90mm plate and incubated at 27°C or 37°C as appropriate. The 98 
MIC was performed in duplicate and determined as the point on the strip where bacteria no longer 99 
grew when in contact with the paper.  100 
Infection of G. mellonella larvae 101 
Experiments were performed in duplicate (n = 15) and results pooled (n = 30). Larvae were 102 
infected with varying inoculum sizes for each mycobacteria strain. Larvae injected with sterile PBS 103 
were included as mock-infected controls. Non-viable-bacteria control larvae received injections of 104 
heat-killed cells at a concentration equal to the largest viable cell inoculum tested. Larval survival was 105 
assessed every 24h for 144h and recorded as dead when no longer responsive to touch. Survival was 106 
plotted as Kaplan-Meir survival curves and comparisons made using log-rank tests. Holm’s corrections 107 
for multiple comparisons [26] was applied. 108 
Antibiotic toxicity was assessed by injecting larvae with 100 mg/kg of each and recording 109 
survival and levels of melanisation on the larval body for 144h. For antibiotic efficacy experiments, 110 
larvae were infected then given single treatments of antibiotic or PBS (mock-treated control) 2h post-111 
infection. For combination experiments, antibiotics were prepared as a single 10 µL dose. 112 
Comparisons of survival were made using log-rank tests on Kaplan-Meir survival curves. In all tests 113 
p≤0.05 was considered significant and Holm’s correction was always applied to account for multiple 114 
comparisons. 115 
Measurement of the internal burden of mycobacteria inside infected larvae  116 
Forty larvae were infected with 10 µL of 4 x 108 c.f.u/mL M. fortuitum NCTC 10394 or 3 x 107 117 
c.f.u/mL M. marinum Strain M. A single dose of antibiotic (10 mg/kg AMK or 50 mg/kg CIP for M. 118 
fortuitum, and 25 mg/kg AMK or 50 mg/kg INH for M. marinum) or PBS (mock-treated control) was 119 
administered 2h post-infection. Five larvae were randomly selected from each group and assessed for 120 
internal bacterial burden at 5, 24, 48, 96 and 144h post-infection.  121 
Preparation of larval suspension for plating was performed as described previously [27]. 122 
Piperacillin (PIP) was selected from a range of antimicrobials to use in selective agar plates as it 123 
inhibited the in vitro growth of microorganisms present in the larval gut but did not affect recovery of 124 
colony forming units of any of the mycobacteria used in this study (data not shown). Larval 125 
suspensions were serially diluted and plated on M7H9 + ADC + PIP selective agar plates then incubated 126 
at 27oC or 37oC as appropriate for 24 – 72h until colonies were visible. 127 
Measuring phagocytosis of FITC-labelled mycobacteria 128 
M. fortuitum NCTC 10394 and M. marinum Strain M cultures were heat killed, resuspended in 129 
0.1 mg/mL FITC (FITC dissolved in 0.2M Na2CO3, 0.2M NaHCO3, pH 9), and incubated in a 27°C shaking 130 
incubator for 30 minutes before washing three times with PBS. 131 
Larvae received injections of PBS, AMK (50 and 5 mg/kg for M. fortuitum, 50 and 2.5 mg/kg 132 
for M. marinum) or EMB (50 mg/kg) as required, 10 minutes before injection with FITC-stained 133 
bacteria (4 x 108 c.f.u/mL for M. fortuitum, 3 x 107 c.f.u/mL for M. marinum). Larvae were incubated 134 
for 1h then injected with 30 µL Galleria saline [28] saturated with phenylthiol urea (PTU) and bled into 135 
individual sterile reaction tubes. The hemolymph was transferred to wells in a 24-well plate prefilled 136 
with 300 µL ice-cold Grace’s insect medium and 13mm round glass coverslips. The plate was incubated 137 
for 1h in the dark in a 27°C low speed shaking incubator. The supernatant was removed and 1 mL 3.7% 138 
formaldehyde added for 20 seconds, then 300 µL 0.4% trypan blue in PBS for 20 minutes. The 139 
coverslips were washed three times with PBS then mounted for examination at 40X magnification 140 
using a Delta Vision fluorescence microscope using differential interference contrast and filters for 141 
FITC (excitation 490 nm/emission 528 nm). Hemocytes were imaged through an appropriately sized z-142 
stack to allow counting of internalised bacteria.  143 
Ten larvae were examined for each condition, with 30 to 70 hemocytes counted per larvae. 144 
Phagocytic rate was calculated as the percentage of total hemocytes that had engulfed one or more 145 
bacteria. Multiple comparisons were assessed with Holm’s correction. 146 
Determination of circulating hemocyte numbers 147 
Adapted from Harding et al. [13]. Fifteen larvae were injected per tested condition. Larvae 148 
were infected with 10 µL of M. fortuitum NCTC 10394 or M. marinum Strain M at an inoculum size of 149 
1.0 x 107 c.f.u/mL. This inoculum size was selected as it induced no lethality over the 48 h duration of 150 
the experiment because the collection of haemolymph from dead larvae was impractical. Following 151 
infection, larvae were inoculated 2h later with PBS, AMK (50 and 5 mg/kg for M. fortuitum, 50 and 2.5 152 
mg/kg for M. marinum) or EMB (50 mg/kg for both species). Larvae were also mock-infected with 10 153 
µL of PBS followed 2h later with AMK (50, 5 or 2.5 mg/kg) or EMB (50 mg/kg) to assess the effects of 154 
these antibiotics on circulating hemocyte numbers in the absence of infection. Unmanipulated 155 
controls were included. Three larvae were randomly selected and injected with 75 µL Galleria saline 156 
[28] at 5, 18.5, 24 and 48 hours post-infection. Hemolymph was bled into individual sterile reaction 157 
tubes and 10 µL was loaded onto an improved Neubauer haemocytometer and the hemocytes 158 
counted with duplicates for each sample. This experiment was performed in triplicate to give n = 9 for 159 
each experimental condition. Holm’s correction was applied to multiple comparisons.  160 
Results 161 
Infection of G. mellonella larvae with viable mycobacteria results in inoculum-size 162 
dependent lethality. 163 
Larvae were infected with a range of inoculum sizes of different mycobacteria. In all cases, 164 
except M. aurum NCTC 10437, as the inoculum size increased larval survival was reduced (Fig 1a, b, d, 165 
e and f). M. aurum NCTC 10437 had no detrimental effect on larval survival at any of the inoculum 166 
sizes tested (Fig. 1c). Notably, heat-killed bacteria had no detrimental effect on larval survival in all 167 
experiments, indicating that larval death was caused by infection with viable M. fortuitum or M. 168 
marinum. There were variations between M. fortuitum and M. marinum virulence – M. marinum 169 
required fewer bacteria (~3 x 107 c.f.u/mL) to decrease larval survival substantially, compared to M. 170 
fortuitum which required up to 30 times more bacteria to have the same effect.   171 
M. marinum NCTC 2275 was not selected for continued experimentation as of the three M. 172 
marinum strains used it had the weakest virulence. M. aurum NCTC 10437 was also not investigated 173 
further as larvae were resistant to infection.  174 
Administration of anti-mycobacterial antibiotics enhances survival of G. mellonella larvae 175 
infected with mycobacteria. 176 
The MICs of a range of anti-mycobacterial antibiotics (AMK, CIP, EMB, INH and RIF) were 177 
measured for each of the mycobacteria to allow comparison of in vitro antibiotic susceptibility with 178 
efficacy of the same drugs versus infected larvae in vivo. The in vitro MICs are described in Table 1. 179 
For all antibiotics tested, the MICs varied widely even between strains of the same species.   180 
Prior to studying the efficacy of the same antibiotics in vivo, larvae were administered a high 181 
dose (100 mg/kg) of each antibiotic alone to determine if any were toxic. Compared to larvae 182 
administered PBS alone, there was no evidence of toxicity to the larvae from any of the antibiotics - 183 
survival was 100% 144h post-injection, and no melanisation was observed on the larval body beyond 184 
the point of injection (data not shown). 185 
The effects of a single dose 2h post-infection of the same antibiotics (Table 1) on survival of 186 
G. mellonella larvae 144h post-infection with mycobacteria are shown in Fig. 2. Complete Kaplan–187 
Meier survival curves are available in Supplementary Data. To readily observe any therapeutic benefit 188 
of antibiotic treatment, larvae were infected with an inoculum of each Mycobacterium known to result 189 
in a high level of mortality (Fig 1). The antibiotic doses administered were selected on the basis of pilot 190 
experiments that screened a wide range of doses for therapeutic benefit (data not shown). An upper 191 
threshold dose of 100 mg/kg was selected for all the antibiotics tested.  192 
AMK was the most successful antibiotic tested, conferring significant therapeutic benefit 193 
against infections by all four mycobacteria tested (Fig. 2a). Comparison of the effectiveness of AMK in 194 
vivo with the in vitro MICs of AMK for each bacterial strain (Table 1) revealed poor correlation. For 195 
example, M. marinum R356933F and M. marinum Strain M had MICs for AMK of 2 and 1 mg/L 196 
respectively. In contrast, the doses of AMK required to successfully treat the in vivo infections with 197 
the same strains were reversed with a single-dose of only 10mg/kg required for the more resistant M. 198 
marinum R356933F and a higher dose of 25 mg/kg for the more sensitive M. marinum Strain M.  199 
CIP treatment (Fig. 2b) was effective for larvae infected with the M. fortuitum strains but 200 
displayed little efficacy versus larvae infected with either strain of M. marinum. Unlike with AMK, this 201 
observation did correlate with the MIC values for each strain (Table 1) as both M. fortuitum strains 202 
were far more sensitive to CIP than the M. marinum strains. 203 
EMB was the least effective antibiotic in these experiments – survival at 144h was almost 204 
invariably indistinguishable from the mock-treated control (PBS) (Fig. 2c). The correlation between the 205 
in vitro and in vivo efficacies of EMB was poor. 206 
INH is largely ineffective for larvae infected with M. fortuitum NCTC 8573 (Fig. 2d), which is 207 
supported by the in vitro data (Table 1). Survival of larvae infected with M. fortuitum NCTC 10394 is 208 
statistically significant, and the MIC results suggest sensitivity to INH, but overall survival was low even 209 
at the highest doses tested. This contrasts with larvae infected with M. marinum – both strains 210 
responded positively to INH treatment and high doses conveyed a long-lasting survival advantage, 211 
supported by the sensitivity to INH in vitro.   212 
RIF significantly improved larval survival after infection with M. marinum (Fig. 2e) and this 213 
correlated with the in vitro MICs (Table 1). However, the M. fortuitum strains had differing responses 214 
to RIF. Mycobacterium fortuitum NCTC 10394 is unresponsive even at high doses, whereas larval 215 
survival significantly improved when M. fortuitum NCTC 8573 was treated with similar doses. Notably, 216 
this did correlate with the MICs because M. fortuitum NCTC 8573 was highly sensitive to RIF in vitro 217 
whilst M. fortuitum NCTC 10394 had the highest MIC of any of the mycobacteria strains tested.  218 
To conclude, in cases where the administered antibiotic enhanced larval survival in vivo, this 219 
occurred in a dose-dependent manner with some doses resulting in near 100% survival compared to 220 
mock-treated controls. However, not all antibiotics were efficacious in vivo and the degree of 221 
correlation between the in vitro sensitivity of the mycobacteria to the drugs and their ability to 222 
enhance larval survival in vivo was variable.   223 
In subsequent experiments, M. fortuitum NCTC 10394 and M. marinum Strain M were used, 224 
as they are the type strains for their species.  225 
Administration of AMK, CIP or INH to larvae infected with mycobacteria reduces the overall 226 
bacterial burden within the larvae.  227 
 The effect that efficacious doses of antibiotics had on the bacterial burden within the larvae 228 
was measured by enumerating viable bacteria in homogenates of larvae that had been exposed to 229 
bacteria and PBS or antibiotic. Doses of AMK, CIP and INH were selected that were previously shown 230 
to confer almost full survival (Fig 2) on larvae infected with inoculum sizes of M. fortuitum NCTC 10394 231 
or M. marinum Strain M that were shown to be lethal to untreated larvae over a period of 144 h (Fig 232 
1). 233 
Infection with M. fortuitum NCTC10394 (4.0 x 108 c.f.u/mL) resulted in a large drop in viable 234 
bacteria over the first 5 h p.i. (Fig. 3a). In contrast, infection with M. marinum Strain M (3.0 x 107 235 
c.f.u/mL) led to only a minor decrease in bacterial numbers over the same time period (Fig 3b). This 236 
obvious difference in the ability of the innate immune system to eliminate the two mycobacteria 237 
strains could explain why larvae need a higher inoculum of M. fortuitum cells to cause significant larval 238 
death compared to the M. marinum species (Fig. 1). Nonetheless, viable mycobacteria were recovered 239 
from both mock (PBS) and antibiotic-treated larvae throughout the entire duration of the experiment 240 
(Fig. 3) despite the fact that the doses of antibiotics administered permitted almost full survival of 241 
infected larvae (Fig 2).  Bacterial burden is mitigated by treatment with the selected antibiotics but 242 
viable bacteria were still detected 144h post-infection with all antibiotics tested. At some time points, 243 
the difference in internal mycobacterial burden between antibiotic-treated and mock-treated larvae 244 
was significantly reduced, potentially accounting for the observed efficacy of these antibiotics (Fig. 2).  245 
Infecting mycobacteria are phagocytosed by G. mellonella hemocytes but phagocytosis is 246 
reduced by exposure to antibiotics. 247 
To determine the fate of mycobacteria in G. mellonella larvae, and how this was influenced by 248 
antibiotic therapy, bacterial phagocytosis was measured by microscopy (Fig 4). The procedure 249 
required to label the mycobacteria with FITC meant that the infecting bacteria were dead (see 250 
Methods). Nonetheless, FITC-labelling permitted the visualisation of internalised mycobacteria and a 251 
representative image of larval hemocytes that have phagocytosed bacteria is shown in Fig 4a. Groups 252 
of larvae were then administered a single 10 µL dose of either PBS, 2.5, 5 or 50 mg/kg AMK or 50 253 
mg/kg EMB. These doses of AMK were selected because 2.5 and 5 mg/kg was shown to have no 254 
therapeutic benefit on infected larvae compared to 50 mg/kg that resulted in almost complete survival 255 
(Fig 2). Similarly, 50 mg/kg EMB was selected because this dose had little therapeutic benefit. In this 256 
way the effect of therapeutic and non-therapeutic doses of antibiotics on phagocytosis could be 257 
measured. After 10 min the larvae administered with either 10 µL PBS or antibiotics were then 258 
inoculated with FITC-labelled mycobacteria and phagocytosis was measured after 1 h at 37°C (Fig 4b).   259 
In larvae exposed to PBS only, over 40% of hemocytes compared to 21% had engulfed one or 260 
more M. fortuitum NCTC 10394 or M. marinum Strain M cells respectively (Fig. 4b). This reflected the 261 
higher infecting inoculum of M. fortuitum NCTC 10394 (4.0 x 108 c.f.u/mL) compared to M. marinum 262 
Strain M (3.0 x 107 c.f.u/mL). For both strains, exposure to a dose of AMK that was shown to be fully 263 
efficacious (50 mg/kg: Fig 2)) resulted in a significant reduction in phagocytosis compared to the PBS 264 
treated controls. Phagocytosis dropped to 21% and 6.9% for M. fortuitum NCTC 10394 or M. marinum 265 
Strain M cells respectively. The effect of non-efficacious doses of AMK and EMB on phagocytosis 266 
differed between M. fortuitum NCTC 10394 and M. marinum Strain M cells. For M. fortuitum NCTC 267 
10394, these doses had no impact on phagocytosis compared to larvae exposed to PBS. In contrast, 268 
ineffective doses of 2.5 mg/kg AMK and 50 mg/kg EMB significantly reduced phagocytosis of M. 269 
marinum Strain M cells to a similar extent as the efficacious dose of 50mg/kg AMK (Fig 4b). 270 
In summary, the larval response in terms of phagocytosis was dependent on the infecting 271 
species of mycobacteria and phagocytosis was reduced by exposure to both efficacious and non-272 
efficacious doses of antibiotics also in a species-dependent fashion. 273 
Administration of antibiotics to uninfected larvae and larvae infected with mycobacteria 274 
induces a significant increase in the number of circulating hemocytes.  275 
The reduction in phagocytosis induced by exposure to antibiotics could perhaps be explained 276 
by changes in the overall numbers of circulating hemocytes. Thus, the effect of exposure to the same 277 
doses of AMK and EMB administered in Fig 4 on circulating hemocytes was measured using 278 
microscopy (Fig 5 and 6). 279 
Larvae were mock-infected with sterile PBS then injected 2 h later with PBS, AMK or EMB. 280 
Relative to PBS treatment, exposure to all doses of each of the antibiotics resulted in a significant, 281 
transient increase in the number of circulating hemocytes within the 3h after antibiotic administration 282 
that disappeared by 24 h. The transient increase in hemocyte number induced by AMK after 5 h was 283 
dose-dependent.  284 
Similarly, when larvae were infected with a viable inoculum of M. fortuitum NCTC 10394 and 285 
M. marinum Strain M cells followed by administration of PBS or the same antibiotic doses of AMK and 286 
EMB used previously (Fig 4 and 5), circulating haemocyte numbers were again significantly higher after 287 
5 h than in larvae mock-infected with PBS (Fig 6). Mock-treatment with PBS also resulted in an increase 288 
in hemocytes but this was much less than that induced by antibiotic treatment. As before, the 289 
antibiotic-induced increase in haemocyte numbers peaked at 5 h and declined noticeably thereafter 290 
(Fig 6).  291 
In summary, the previous data revealing that antibiotics reduced the phagocytic rate of FITC-292 
labelled, dead mycobacteria (Fig. 4) could perhaps be explained by the increase in circulating 293 
hemocyte numbers that was induced by exposure to the antibiotics alone (Fig 5) or by antibiotics 294 
administered to larvae infected with viable mycobacteria (Fig 6). For example, increased numbers of 295 
hemocytes could mean that many may not encounter bacteria to phagocytose, thereby reducing the 296 
overall quantity of hemocytes containing bacteria.  297 
Antibiotic combination treatments provide greater therapeutic benefit to larvae infected 298 
with mycobacteria than antibiotic monotherapy.   299 
Treatment of M. tuberculosis infections usually involves administration of combinations of 300 
antibiotics for optimal therapy. To mimic combination therapy with infected G. mellonella larvae, and 301 
to observe whether typical combination treatments were also more efficacious in this model system, 302 
three antibiotic combinations were selected using WHO treatment guidelines [29]. Thus, the 303 
therapeutic benefit conferred by three multiple drug combinations was studied: one triple 304 
combination (EMB+INH+RIF), and two quadruple combinations (AMK+EMB+INH+RIF and 305 
CIP+EMB+INH+RIF) (Fig 7). The doses of the individual antibiotics administered within the combination 306 
regimens were selected on the basis that they provided minimal therapeutic benefit when given as 307 
monotherapy to larvae infected with mycobacteria (Fig. 2). When these non-efficacious doses were 308 
combined, larval survival improved significantly compared to mock-treated groups (PBS) (Fig 7) and to 309 
larvae administered with a doses of each drug individually (Fig. 2). Thus, larval model reflects the 310 
enhanced efficacy of antibiotics administered in combinations as practiced in clinical settings.   311 
Discussion 312 
The data reported here shows that G. mellonella larvae could be employed as a valuable in 313 
vivo infection model for several mycobacteria species and allow the therapeutic effects of antibiotic 314 
treatments to be quantified.   315 
The majority of the mycobacteria examined can kill G. mellonella larvae, and the numbers of 316 
viable infecting bacteria correlates negatively with larval survival. The exception is M. aurum NCTC 317 
10394, although M. aurum is exclusively reported as infectious in immuno-compromised humans [30, 318 
31] (unlike M. fortuitum [32, 33] and M. marinum [17, 34]) so non-pathogenicity in immunocompetent 319 
larvae is perhaps unsurprising.  320 
Ethambutol, isoniazid and rifampicin were selected for their historic inclusion in standard TB 321 
treatment regimens [35] and amikacin and ciprofloxacin for their use as second-line treatments for 322 
MDR-TB [36]. All five have been used with M. fortuitum [32, 37–41] and M. marinum [17, 42, 43] in 323 
vitro and in vivo, although in vivo experiments predominantly use combination treatments. When used 324 
to treat human infections, amikacin can be used at 15 mg/kg for M. fortuitum infections [32] or 400 325 
mg daily for M. marinum [44]. Ciprofloxacin has been used at approximately 8 mg/kg for M. fortuitum 326 
infections [45] and 500 mg twice daily for M. marinum [46]. Ethambutol, isoniazid and rifampicin are 327 
not prescribed for M. fortuitum infections, although daily doses of ethambutol at 25 mg/kg and 328 
rifampicin at 600 mg is a well-established treatment for M. marinum [47] and isoniazid at 10 mg/kg 329 
has been shown to be an effective treatment for M. marinum in zebrafish [48]. Whilst the efficacious 330 
doses of these drugs in G. mellonella larvae were different, they were at least comparable and of a 331 
similar order of magnitude.  332 
The effective antibiotics generally improved larval survival in a dose-dependent manner 333 
compared with mock-treated larvae (Fig. 2). However, varied sensitivity to each antibiotic was 334 
observed between strains and several antibiotics had no therapeutic effect at the highest dose tested. 335 
Combination therapy that included some of the ineffective antibiotics improved overall efficacy – 336 
some combinations gave almost 100% larval survival across the 144h experiment. Considering the 337 
necessity of employing antibiotic combinations when treating patients infected with mycobacteria, 338 
this result is key to indicating the potential role of G. mellonella in testing further novel combination 339 
treatments. In addition, measurement of the bacterial burden (Fig. 3) indicated that efficacious doses 340 
of antibiotics that permitted almost full survival of the infected larvae only reduced the overall 341 
numbers of bacteria within the larvae without eliminating them. This implies that a certain threshold 342 
number of mycobacteria are required to cause larval death and that the larvae are readily able to 343 
survive despite still being infected with bacterial numbers that are below this apparent lethal 344 
threshold. It is not clear from this work what contribution to the measured efficacy of the antibiotics 345 
is due to the direct inhibitory action of the drugs on the infecting bacteria, and what contribution is 346 
due to the apparent stimulation of the innate immune system (in the form of increased hemocyte 347 
numbers; Fig 5 and 6) that is triggered upon exposure to the antibiotics. It would seem likely that both 348 
actions contribute to the measured efficacy of the drugs.  349 
Human phagocytic cells have been assessed against a multitude of antimicrobials and 350 
pathogens to determine if phagocytosis is enhanced, supressed or unaffected (reviewed in [49]), and 351 
is it well established that a number of medications can reduce [50] or increase [51] the number of 352 
circulating immune cells in humans. A reduction in the number of circulating white blood cells is a very 353 
rare side-effect when using anti-tuberculosis medications [52] – there is no suggestion that any of the 354 
drugs in this study cause a reliable change in the number of circulating immune cells in humans. 355 
Interactions between antibiotics and the larval immune system may explain why antibiotics cause such 356 
a significant increase in the number of circulating hemocytes in the hours post-injection (Fig. 5). A 357 
similar response using antifungals has been shown with G. mellonella elsewhere [53, 54]. Considering 358 
the increase is not seen when larvae are mock-treated with PBS, this suggests that antimycobacterials 359 
trigger a non-specific immune response. Increased numbers of circulating hemocytes has been shown 360 
to  correlate with improved larval survival for fungal infections [55], yet here, the antibiotic EMB 361 
increased hemocyte density but did little to improve larval survival so this correlation may not be 362 
universally applicable.  363 
The lack of correlation between the in vitro efficacy of the antibiotics (Table 1) and the in vivo 364 
data (Fig. 2) is not necessarily detrimental to the conclusions of this study. A useful application of this 365 
model is to test drugs which have only been examined in vitro to determine possible variances in the 366 
in vivo results, and it is vital not to overly extrapolate in vitro data to predict in vivo results as there 367 
are often discrepancies between the two.  368 
Existing whole-organism models for mycobacterial, particularly M. tuberculosis, infections 369 
include mice, rats, guinea pigs, rabbits, cattle, and primates). However, all present problems with cost, 370 
housing requirements, operating regulations, and ethical concerns. Non-mammalian models can also 371 
be a useful tool. For example, zebrafish are not natural hosts of M. tuberculosis, but M. marinum 372 
infections eventually produce lipid-rich and necrotic granulomas [56] in adult and larval fish, despite 373 
the immature fish larvae having no adaptive immune system at that developmental stage [15].  374 
Drosophila melanogaster (fruit fly) is becoming a well-established model for M. marinum [57]. 375 
Infected flies show evidence of “wasting” [58], a key symptom in humans. Fly hemocytes engulf M. 376 
marinum which replicate inside the hemocytes and are eventually released, then found extracellularly 377 
to the host cells [59] similar to M. tuberculosis with human immune cells. Unfortunately, fruit flies are 378 
reared at 18-29oC and are difficult to inoculate with specific volumes. Circulating hemocytes can only 379 
be collected from fly larvae, [60], meaning that the short term effects of infection on circulating 380 
hemocytes can only be examined in larval flies – long term experiments must use adult flies [59]. 381 
For these reasons, Galleria mellonella larvae are an attractive model organism for screening novel 382 
compounds against mycobacterial infections. They thrive at 37oC, can be easily and consistently 383 
inoculated with specific quantities of bacteria and drugs, and hemocytes can be collected from their 384 
hemolymph long after infection. Similarly to D. melanogaster, experiments are limited to the life cycle 385 
of the larvae, and larvae are unlikely to be of use in persistence models of latent TB infections. 386 
However, considering the pressure to locate new and novel compounds to treat mycobacterial 387 
infections, especially drug-resistant strains, having access to a convenient in vivo model early in the 388 
drug discovery and development timeline could be invaluable. We suggest that G. mellonella would 389 
be a valuable tool for testing compounds with efficacy against mycobacteria and may provide useful 390 
evidence to support further work with clinically relevant cell lines or small-mammal trials.  391 
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Figure legends  550 
Figure 1. Effect of infection with a range of mycobacteria species and strains on survival of G. mellonella 
larvae. The data is presented as Kaplan-Meir survival curves. The number of cells injected (10 µL) into each 
larva is shown beside each panel as colony forming units (c.f.u) per mL (highest cell concentrations, black 
filled squares; middle concentration, grey filled triangles; lowest concentration, black filled circles). 
Controls of larvae mock-infected with PBS (uninfected, grey crosses) and injected with heat-killed bacteria 
at an equivalent concentration to the highest c.f.u/mL used (heat killed, black open squares) are also 
shown. n = 30. 
Figure 2. Effect of administration of a single dose of a range of antimycobacterial antibiotics on survival of 
G. mellonella larvae 144h post-infection with four mycobacteria species and strains. Larvae were infected 
with viable bacteria then treated 2 hours post-infection (M. fortuitum NCTC 10394, 4 x 108 c.f.u/mL; M. 
fortuitum NCTC 8573, 5 x 108 c.f.u/mL; M. marinum Strain M, 3 x 107 c.f.u/mL; M. marinum R356933F, 9 x 
108 c.f.u/mL). Larval survival was monitored for 144h post-infection. The doses of antibiotic used are 
indicated below each bar in mg/kg. Each bar represents mean survival ± SEM after 144h. Mock-treated 
larvae were injected with PBS 2 hours post-infection. Any doses which conveyed a significant (p < 0.05, Log-
Rank test on complete Kaplan-Meier curves) increase in larval survival across the full 144h observation are 
indicated with a star (*). Multiple comparisons were corrected with Holm’s correction. n = 30. AMK, 
amikacin; CIP, ciprofloxacin; EMB, ethambutol; INH, isoniazid; RIF, rifampicin.  
Figure 3. The effect of infection with mycobacteria and subsequent mock-treatment with PBS or antibiotics 
on the bacterial burden within G. mellonella larvae. Larvae were infected with M. fortuitum NCTC 10394 (4 
x 108 c.f.u/mL) (a) and M. marinum Strain M (3 x 107 c.f.u/mL) (b). Antibiotics or PBS were administered 2h 
post-infection at the doses indicated. Mock-treated larvae are represented by grey filled triangles. Larvae 
treated with amikacin, ciprofloxacin and isoniazid are represented with grey circles, open black squares 
and black hatched diamonds respectively. Data shows mean ± SEM with each marker representing the 
average c.f.u/mL for five larvae in each condition at each time point. Asterisks indicate significant 
differences between groups treated with an antibiotic and those that received PBS (p < 0.05, Mann-
Whitney U-test). Multiple comparisons were corrected with Holm’s correction. AMK, amikacin; CIP, 
ciprofloxacin; INH, isoniazid. 
Figure 4. Effect of exposure to PBS or antibiotics on phagocytosis of FITC-labelled mycobacteria by G. 
mellonella hemocytes. Panel (a) represents a typical captured image of an optical slice through G. 
mellonella haemocytes showing internalised, fluorescent M. marinum. The proportion of larval hemocytes 
with phagocytosed M. fortuitum NCTC 10394 or M. marinum Strain M after 1h of incubation in the presence 
of efficacious or non-efficacious doses of AMK (50 mg/kg; 2.5 or 5 mg/kg, respectively) or a non-efficacious 
dose of EMB (50 mg/kg) and compared to a mock-treated control (PBS) is shown in (b). Data is from 10 
larvae, 30 – 70 hemocytes examined per larvae, with mean ± SEM. n = 10. (p < 0.05, unpaired, two-tailed 
Student’s t-test with Holm’s correction applied for multiple comparisons). AMK, amikacin; EMB, 
ethambutol.  
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 552 
 553 
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Figure 5. Effect of exposure to antibiotics on overall numbers of circulating G. mellonella hemocytes. Larvae 
were mock-infected with PBS followed 2 hours later by administration of PBS or doses of AMK (2.5, 5 or 50 
mg/kg) or EMB (50 mg/kg). Numbers of hemocytes in the larval hemolymph were then counted at 5, 18.5, 
24 and 48 h post the initial mock-infection with PBS. The number of hemocytes is presented relative to 
larvae mock-infected and treated with PBS. Data is from 9 larvae per time-point showing mean ± SEM. (p < 
0.05, unpaired, two-tailed Student’s t-test with Holm’s correction applied for multiple comparisons) AMK, 
amikacin; EMB, ethambutol.  
 
Figure 6. Effect of infection with mycobacteria and subsequent treatment with PBS or antibiotics on overall 
numbers of circulating G. mellonella hemocytes. Larvae were infected with M. fortuitum NCTC 10394 or M. 
marinum Strain M (1.0 x 107 c.f.u/mL) then 2 h post-infection were treated with efficacious or non-
efficacious doses of AMK (50 mg/kg; 2.5 or 5 mg/kg, respectively) or a non-efficacious dose of EMB (50 
mg/kg) or PBS as a mock-treated control. Numbers of hemocytes in the larval hemolymph were then 
counted at 5, 18.5, 24 and 48 h post-infection. The number of hemocytes is presented relative to larvae 
mock-infected and treated with PBS. (p < 0.05, unpaired, two-tailed Student’s t-test with Holm’s correction 
applied for multiple comparisons). Data is from 9 larvae per time-point showing mean ± SEM. AMK, 
amikacin; EMB, ethambutol.  
 
Figure 7. Effect of antibiotic monotherapy or combination therapy on survival of G. mellonella larvae 144 h 
post-infection with mycobacteria. Larvae were infected with M. fortuitum NCTC 10394 (4 x 108 c.f.u/mL) 
(a) or M. marinum Strain M (3 x 107 c.f.u/mL) (b) followed by treatment 2 h post-infection with a single 
dose of either PBS, antibiotic monotherapy or antibiotic combinations. Antibiotic monotherapy doses for 
M. fortuitum were 5 mg/kg AMK, 2.5 mg/kg CIP, 100 mg/kg EMB, 5 mg/kg INH and 30 mg/kg RIF, and for 
M. marinum were 2.5 mg/kg AMK, 50 mg/kg CIP, 100 mg/kg EMB, 5 mg/kg INH and 10 mg/kg RIF. The 
combination treatments consisted of the same drug concentrations as above but pooled to a make a single, 
combination dose. Data shows mean survival ± SEM after 144 h. * indicates a significant increase in survival 
of combination therapy compared to each individual monotherapy (p < 0.05, Log-rank test on complete 
Kaplan-Meier curves with Holm’s correction applied for multiple comparisons).  
Controls of larvae mock-infected with PBS are also shown. n = 30. AMK, amikacin, CIP, ciprofloxacin; EMB, 
ethambutol; INH, isoniazid; RIF, rifampicin.  
 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
mg/L 
 M. fortuitum M. marinum 
 NCTC 10394 NCTC 8573 Strain M R356933F 
AMK 0.12 – 0.25 0.12 – 0.25 1.0 2.0 
CIP 0.008 0.05 0.5 0.25 – 0.5 
EMB 2.0 >256 0.125 – 0.19 0.19 – 0.25 
INH 1.0 – 2.0 >256 4.0 – 6.0 2.0 – 3.0 
RIF 12.0 <0.016 6.0 – 8.0 0.38 – 0.5 
AMK, amikacin; CIP, ciprofloxacin; EMB, ethambutol; INH, isoniazid; RIF, rifampicin.   
Table 1. MICs of five antibiotics for M. fortuitum NCTC 10394, M. fortuitum 
NCTC 8573, M. marinum Strain M and M. marinum R356933F using three 
independent biological replicates. 
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Supplementary data – Kaplan-Meier survival curves for antibiotic susceptibility experiments (pages 669 
1-3) and antibiotic combinations (page 4) 670 
The antibiotic used is at the top of each grouping, and the species and strain of Mycobacteria used at 671 
the top of each curve. AMK, amikacin; CIP, ciprofloxacin; EMB, ethambutol; INH, isoniazid; RMP, 672 
rifampicin. 673 
The mock-treated larvae are indicated with a grey line without line markers. The highest antibiotic 674 
dose is an unbroken black line with black, filled square markers. Middle doses have a dashed grey line 675 
and filled grey triangle markers, and the lowest dose have a dotted black line with a filled black circle 676 
marker. A mock-infected control is shown with grey crossed markers and a dashed grey line.  677 
The doses used in mg/kg are shown to the right of each curve. Any doses that increased larval survival 678 
significantly above the survival of the mock-treated control have an asterisk by the dose.  679 
 680 
 681 
Kaplan-Meir survival curves for the antibiotic combination experiments. Each of the single antibiotic 682 
doses are shown in pale grey, with the initial of the antibiotic as the point marker. A, amikacin; C, 683 
ciprofloxacin; E, ethambutol; I, isoniazid; R, rifampicin. The combinations are shown in black, with the 684 
combinations used listed on the right hand side of the figure. The mg/kg are included (eg. A5 describes 685 
a 5 mg/kg dose of amikacin). An asterisk next to this label means that the survival is significantly higher 686 
than the mock-treated control (log rank test, Holm’s correction applied).  687 
 688 
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